All companies › CORT

CORT · CORCEPT THERAPEUTICS INC

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells9
Research cases0
Last filing2026-10-02

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-01 — Maduck Sean · sold 413 @ $115.54 2026-10-01 — Lyon Joseph Douglas · sold 810 @ $115.40 2026-10-02 — Maduck Sean · sold 15,843 @ $116.12 2026-10-02 — Maduck Sean · sold 8,744 @ $116.55 2026-10-02 — Lyon Joseph Douglas · sold 4,446 @ $115.70 2026-10-02 — Lyon Joseph Douglas · sold 4,744 @ $116.54 2026-10-02 — Vieira Roberto Wandenkolk · sold 1,100 @ $114.52 2026-10-02 — Vieira Roberto Wandenkolk · sold 2,086 @ $115.73 2026-10-02 — Vieira Roberto Wandenkolk · sold 5,147 @ $116.58
2026-10-012026-10-02

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Maduck Sean See Remarks
Lyon Joseph Douglas See Remarks
Vieira Roberto Wandenkolk President, Oncology
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $CORT is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-02', 'insider_name': 'Maduck Sean', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 15843.0, 'price': 116.1233, 'value': 1839741.44, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Maduck Sean', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 8744.0, 'price': 116.5534, 'value': 1019142.93, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Lyon Joseph Douglas', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 4446.0, 'price': 115.697, 'value': 514388.86, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Lyon Joseph Douglas', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 4744.0, 'price': 116.5407, 'value': 552869.08, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Vieira Roberto Wandenkolk', 'insider_title': 'President, Oncology', 'transaction_type': 'Open-market sell', 'shares': 1100.0, 'price': 114.5205, 'value': 125972.55, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Vieira Roberto Wandenkolk', 'insider_title': 'President, Oncology', 'transaction_type': 'Open-market sell', 'shares': 2086.0, 'price': 115.7298, 'value': 241412.36, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Vieira Roberto Wandenkolk', 'insider_title': 'President, Oncology', 'transaction_type': 'Open-market sell', 'shares': 5147.0, 'price': 116.585, 'value': 600062.99, 'is_buy': False}, {'transaction_date': '2026-10-01', 'insider_name': 'Maduck Sean', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 413.0, 'price': 115.5373, 'value': 47716.9, 'is_buy': False}, {'transaction_date': '2026-10-01', 'insider_name': 'Lyon Joseph Douglas', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 810.0, 'price': 115.3985, 'value': 93472.79, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for CORT today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.